Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro® and Placebo

Launched by SPEAR PHARMACEUTICALS · Jun 1, 2010

Keywords

ClinConnect Summary

Not required

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Normal, healthy male and female children and adult
• • Written and verbal informed consent must be obtained. Patients age 12 to 17 (inclusive) must sign an assent for the study and a parent or a legal guardian must sign the informed consent.
• • Women of child-bearing potential must be non-pregnant and non-nursing, and must be willing to avoid pregnancy during the course of the study and during the menstrual cycle following completion of their participation in the study.
• • Able to refrain from the use of all other topical acne medications or antibiotics during the treatment period.
• • Considered reliable and capable of understanding their responsibility and role in the study.
• Exclusion Criteria:
• • Significant history or clinical evidence of auto-immune, cardiovascular, gastrointestinal, hematological, hepatic, neurological, pancreatic, or renal disease.
• • Abnormal pre-existing skin condition which might affect the normal course of acne vulgaris (e.g., eczema, psoriasis, albinism, or chronic vesiculobullous disorders).
• • Use topical acne therapy during the two week period prior to study initiation.
• • Use of systemic retinoid treatment within six months prior to study initiation.
• • Pregnant or breast-feeding.
• • Serious psychological illness.
• • Participation in any clinical research study during the 30 day period preceding study initiation.